Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 10, Issue 6, Pages 1499-1504Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.27985
Keywords
Campylobacter; conjugate vaccines; GBS; diarrheal disease; capsular polysaccharide
Categories
Funding
- Military Infectious Diseases Research Program [6000.RAD1.DA3.A0308, UO1A1082105]
Ask authors/readers for more resources
Campylobacter jejuni is a major cause of diarrheal disease and results in high levels of morbidity and economic loss in both industrialized and developing regions of the world. To date, prior vaccine approaches have failed to confer protection against this enteric pathogen. Key challenges to the development of a practical Campylobacter vaccine for human use include a lack of understanding of Campylobacter pathogenesis and well-defined immune correlates of protection. With the discovery that C. jejuni expresses a capsule polysaccharide associated with virulence, a conjugate vaccine approach is currently being evaluated. Conjugate vaccines have been successfully developed and implemented against other invasive mucosal pathogens including Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae. Furthermore, Shigella-based conjugate vaccines based on lipopolysaccharide have shown promising results in field trials. A prototype C. jejuni conjugate vaccine is currently entering human testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available